[Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].
The present article briefly reviews the main types of pharmacoeconomic analyses that evaluate the costs associated with HIV infection and the efficiency of antiretroviral therapy in general. The results of several pharmacoeconomic analyses applied to the selection of antiretroviral drugs in distinct clinical scenarios are also presented. Finally, we analyze the advantages, in terms of efficiency, of lopinavir/ritonavir as induction-maintenance therapy, both in terms of saving the direct costs of treatment and in possibly reducing the costs due to the management of the adverse effects of nucleoside analogs.
Escobar Rodríguez
Ismael
I
Servicio de Farmacia, Hospital Infanta Leonor, Servicio Madrileño de Salud, Madrid, España. iescobar@sefh.es
Esteban Alba
Concepción
C
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003363:Cost Control; D003362:Cost-Benefit Analysis; D004180:Direct Service Costs; D004338:Drug Combinations; D016527:Drug Costs; D064420:Drug-Related Side Effects and Adverse Reactions / Q000191:economics; D005062:European Union / Q000191:economics; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D011306:Prescription Fees; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir